Physician profile
Suresh Kumar
NPI 1972581874
$2,008.29
in general payments reported to CMS, 2019-2025
32 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $77.62 · 2021: $391 · 2022: $345 · 2023: $210 · 2024: $378 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.68 | 2021-2025 | |
| Lilly USA, LLC | $323.27 | 2019-2024 | Amyvid |
| Lundbeck LLC | $156.45 | 2019-2025 | Vyepti |
| Amgen INC. | $102.94 | 2022 | |
| Eisai INC. | $83.84 | 2024 | |
| Novartis Pharmaceuticals Corporation | $83.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $78.76 | 2020-2023 | Austedo Xr, Austedo |
| Genentech USA, INC. | $74.14 | 2019-2022 | |
| Sk Life Science, INC. | $64.68 | 2020-2023 | |
| Genzyme Corporation | $60.47 | 2019-2022 | |
| Ucb, INC. | $60.21 | 2019-2021 | |
| Csl Behring | $55.00 | 2019 | |
| Kyowa Kirin, INC. | $54.97 | 2021-2022 | |
| Pfizer INC. | $47.04 | 2023-2024 | |
| Sunovion Pharmaceuticals INC. | $44.26 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $44.24 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Greenwich Biosciences, INC. | $40.68 | 2021 | |
| Celgene Corporation | $31.77 | 2021-2023 | |
| Neurelis, INC. | $30.32 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $28.56 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $24.71 | 2022 | |
| Acorda Therapeutics, INC | $24.43 | 2019 | |
| Avanir Pharmaceuticals, INC. | $19.20 | 2019 | |
| Abbott Laboratories | $18.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.49 | 2021 | |
| Emd Serono, INC. | $16.17 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.43 | 2024 | Andexxa |
| Tg Therapeutics, INC. | $13.71 | 2023 | |
| Amneal Pharmaceuticals LLC | $13.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.02 | 2020 | |
| Mdd US Operations, LLC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.